/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Black Diamond Therapeutics

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.72 -0.2203(-22.03%) BDTX at 04 Dec 2025 04:26 PM Biotechnology
Lowest Today 2.24
Highest Today 3.36
Today’s Open 3.355
Prev. Close 3.45
52 Week High 4.94
52 Week Low 1.20
Day’s Range: Low 2.24 High 3.36
52-Week Range: Low 1.20 High 4.94
1 day return -
1 Week return -30.32
1 month return -26.48
3 month return -7.3
6 month return +4.92
1 year return +8.33
3 year return +44.83
5 year return -92.27
10 year return -

Institutional Holdings

T. Rowe Price Investment Management,Inc. 18.46

BB Biotech AG Ord 14.96

Vestal Point Capital LP 9.84

NEA Management Company, LLC 7.81

Bellevue Group AG 4.80

T. Rowe Price Small-Cap Stock 4.45

T. Rowe Price US Small-Cap Core Equity 4.39

T. Rowe Price Small-Cap Value 4.38

Vanguard Group Inc 3.69

TANG CAPITAL MANAGEMENT LLC 3.64

Vanguard Total Stock Mkt Idx Inv 2.29

T. Rowe Price Instl Small-Cap Stock 2.28

T. Rowe Price U.S. SC Core Eq Tr-D 2.22

T. Rowe Price U.S. SC Value Eq Tr-D 2.19

BlackRock Inc 1.92

Siren, L.L.C. 1.84

Millennium Management LLC 1.66

Marshall Wace Asset Management Ltd 1.30

T. Rowe Price US Smlr Coms Eq A 0.94

BlackRock Health Sciences Term Trust 0.89

Awm Investment Company Inc 0.88

Geode Capital Management, LLC 0.87

Dafna Capital Management LLC 0.83

Vanguard Institutional Extnd Mkt Idx Tr 0.82

Dimensional Fund Advisors, Inc. 0.80

FMR Inc 0.73

Goldman Sachs Group Inc 0.62

J. Goldman & Co LP 0.57

UBS Group AG 0.55

Fidelity Enhanced Small Cap ETF 0.49

GSA Capital Partners LLP 0.42

Fidelity Extended Market Index 0.42

Stifel Financial Corp 0.39

Northwestern Mutual Ser Small Cap Value 0.35

T. Rowe Price Small-Cap Value Equity 0.35

iShares Micro-Cap ETF 0.19

Vanguard VIF Small Co Gr 0.16

Bridgeway Ultra-Small Company Market 0.15

T. Rowe Price U.S. Equities Tr 0.15

Fidelity VIP Disciplined Small Cap Init 0.15

Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 196.56 M

PB Ratio 1.7253

PE Ratio 9.3243

Enterprise Value 101.81 M

Total Assets 122.64 M

Volume 10181629

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-437000 -0.4M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-82442000 -82.4M, FY22:-84520000 -84.5M, FY21:-123203000 -123.2M, FY20:-65479000 -65.5M, FY19:-41143000 -41.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:70000000 70.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-86000 -0.1M, Q1/2025:70000000 70.0M, Q3/2024:-86000 -0.1M, Q2/2024:-86000 -0.1M

Quarterly Net worth Q3/2025:-8498000 -8.5M, Q2/2025:-10561000 -10.6M, Q1/2025:56542000 56.5M, Q3/2024:-15557000 -15.6M, Q2/2024:-19909000 -19.9M

Fund house & investment objective

Company Information Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 24

Industry Biotechnology

CEO Dr. Mark A. Velleca M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow